(Journal Article): Visceral Obesity and Hemostatic Profile in Patients with Type 2 Diabetes: The Effect of Gender and Metabolic Compensation
 
Kozek E, Katra B, Malecki M, Sieradzki J (Department of Metabolic Diseases, Jagiellonian University, Medical College, 15 Kopernika Street, 31-501 Krakow, Poland, ela_kozek(at)yahoo.com )
 
IN: Rev Diabetic Stud 2004; 1(3):122-128
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: BACKGROUND: Type 2 diabetes (T2DM) patients are characterized by a very high risk of cardiovascular diseases. Among the factors that are responsible for this phenomenon are abdominal obesity and hemostatic abnormalities. AIM OF THE STUDY: To examine the association of the markers of coagulation and fibrinolysis with the parameters of abdominal obesity and metabolic compensation in T2DM patients. METHODS: 46 T2DM patients participated in the study: 24 men (mean age 61.1 ± 7.9 years) and 22 postmenopausal women (mean age 62.6 ± 8.7 years). In each patient the content and distribution of fatty tissue was measured by a dual energy X-ray absorptiometry method (DEXA). The central abdominal fat/gynoid hip fat (CAF/GF) ratio was calculated. The following hemostatic parameters were measured: fibrinogen (Fb), factor VII (fVII), antithrombin III (ATIII), C protein (pC), tissue plasminogen activator inhibitor (PAI-1) and alpha 2 antiplasmin (alpha2 AP). In addition, the biochemical indices of metabolic compensation were measured: HbA1c, glucose levels and lipids. RESULTS: Patients of both genders were divided according to median CAF/GF ratio. The activity of PAI-1 was significantly higher in women with CAF/GF ratio >= 0.88 as compared to those with CAF/GF < 0.88 (2.64 ± 1.28 vs. 1.61 ± 0.27 U/ml, p < 0.05). The activity of ATIII was significantly lower in men with CAF/GF ratio >= 1.17, as compared to those with CAF/GF < 1.17 (105.10 ± 10.02 vs. 113.42 ± 10.72 %, p < 0.05). There was a significant correlation between the CAF/GF ratio and the activity of PAI-1 in women (r = 0.30, p < 0.05). In addition, in men the CAF/GF ratio was negatively correlated with ATIII activity (r = -0.44, p < 0.05). Multiple stepwise regression analysis demonstrated independent association between the CAF/ GF ratio and the activity of PAI-1 (p < 0.001), and between the CAF/GF ratio and the activity of alpha2 AP (p < 0.01). There was an independent association between the concentration of HbA1c and the concentration of Fb (p < 0.001) and between triglycerides and the activity of fVII (p < 0.01). CONCLUSIONS: The results of our study show that the patients with T2DM and with higher markers of abdominal obesity measured by DEXA show fibrinolysis impairment and thrombinogenesis elevation compared to those with lower abdominal obesity markers. Independent factors determining hypercoagulation also include metabolic control and lipids. Hemostatic disorders place subjects with diabetes and abdominal obesity at risk of developing vascular complications.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Vague J. The degree of masculine differentiation of obesities: a factor for determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956. 4:20-33.
2. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991. 14:1132-1143.
3. Reaven GM. The role of insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 1992. 41:16-19.
4. Despres JP. Abdominal obesity as an important component of insulin-resistance syndrome. Nutrition 1993. 9:452-459.
5. Rios MS. Relationship between obesity and the increased risk of major complications in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1998. 28(suppl. 2):14-18.
6. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women. Diabetes 1996. 45:633-638.
7. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999. 22(suppl. 3):C25-C30.
8. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000. 15:897-907.
9. Loskutoff DJ, Samad F. The adipocyte and hemostatic balance in obesity studies. Arterioscler Thromb Vasc Biol 1998. 18:1-6.
10. Samad F, Pandey M, Loskutoff DJ. Tissue factor gene expression in the adipose tissues of obese mice. Proc Natl Acad Sci 1998. 95:7591-7596.
11. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992. 55:950-954.
12. Svendsen OL, Hassager C, Bergmann I, Christiansen C. Measurement of abdominal and intra-abdominal fat in postmenopausal women by dual energy X-ray absorptiometry and anthropometry: comparison with computerized tomography. Int J Obes 1993. 17:45-51.
13. Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurement of abdominal and visceral fat with computed tomography and dual energy X-ray absorptiometry. Am J Clin Nutr 1995. 61:274-278.
14. Chang Ch, Wu Ch, Lu F, Wu J, Chiu N, Yao W. Discriminating glucose tolerance status by regions of interest of dual-energy X-ray absorptiometry. Diabetes Care 1999. 22:1938-1943.
15. Kamel EG, McNeiull G, Han TS, Smith FW, Avenell A, Davidson L, Tothill P. Measurement of abdominal fat by magnetic resonance imaging, dual-energy X- ray absorptiometry and anthropometry in non-obese men and women. Int J Obes Relat Metab Disord 1999. 23:686-692.
16. Paradisi G, Smith L, Burtner C, Leaming R, Garvey WT, Hook G, Johnson A, Cronin J, Steinberg HO, Baron AD. Dual energy X-ray absorptiometry assessment of fat mass distribution and its association with the insulin resistance syndrome. Diabetes Care 1999. 22:1310-1317.
17. Ross R, Shaw K, Martel Y, De Guise J, Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am J Clin Nutr 1993. 57:470-475.
18. Park Y-W, Heymsfield SB, Gallagher D. Are dual-energy X-ray absorptiometry regional estimates associated with visceral adipose tissue mass? Int J Obes 2002. 26:978-983.
19. Lemieux S, Prud'Homme D, Nadeau A, Tremblay A, Bouchard C, Despres J-P. Seven-year changes in body fat and visceral adipose tissue in women. Diabetes Care 1996. 19:983-991.
20. Toth MJ, Tchernof A, Sites CK, Poehlman ET. Effect of menopausal status on body composition and abdominal fat distribution. Int J Obes Relat Metab Disord 2000. 24:226-231.
21. Rissanen P, Hamalainen P, Vanninen E, Tenhunen-Eskelinen M, Uusitupa M. Relationship of metabolic variables to abdominal adiposity measured by different anthropometric measurements and dual-energy X-ray absorptiometry in obese middle-aged women. Int J Obes Relat Metab Disord 1997. 21:367-371.
22. Stoney RM, Best JD, Walker KZ, O'Dea K. Regional adiposity and haemostatic profile in diabetic women and women with normal glucose tolerance. Diabetologia 1998. 41(suppl.)1: A410, 1614.
23. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997. 46:860-867.
24. Park YS, Park S, Park KS, Kim SY, Lee HK, Koh CS, Min HK, Kim JQ. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea. Diabetes Res Clin Pract 1994. 24:25-31.
25. Fendri S, Roussel B, Lormeau B, Tribout B, Lalau JD. Insulin sensitivity, insulin action, and fibrinolysis activity in nondiabetic and diabetic obese subjects. Metabolism 1998. 47:1372-1375.
26. Cho YW, Oh DY, Kim SJ, Hong SY, Lee HC, Huh KB. Euglobulin fibrinolytic activity in NIDDM patients. Diabetes Res Clin Pract 1991. 13:139-145.
27. Mertens I, Van der Planken M, Corthouts B, Wauters M, Peiffer F, De Leeuw I, Van Gaal L. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women. Horm Metab Res 2001. 33:602-607.
28. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat Accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996. 16:368-374.
29. Cerriello A, Gugliano D, Quatraro A. Induced hyperglycaemia alters antithrombin III activity but not its plasma concentration in healthy normal subjects. Diabetes 1987. 36:320-325.
30. Gabazza EC, Takeya H, Deguchi H, Sumida Y, Taguchi O, Murata K, Nakatani K, Yano Y, Mohri M, Sata M, Shima T, Nishioka J, Suzuki K. Protein C activation in NIDDM patients. Diabetologia 1996. 39:1455-1461.
31. Veglio M, Gruden G, Mormile A, Girotto M, Rossetto P, D'Este P, Cavallo-Perin P. Anticoagulant protein C activity in non-insulin-dependent diabetic patients with normoalbuminuria and microalbuminuria. Acta Diabetol 1995. 32:106-109.
32. Imperatore G, Riccardi G, Iovine C, Rivellese A, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998. 21:649-654.
33. Asakawa H, Tokunaga K, Kawakami F. Relationship of abdominal fat with metabolic disorders in diabetes mellitus patients. Diabetes Res Clin Pract 2002. 55:139-149.
34. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, Arveiler D, Juhan-Vague I. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction - the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 1998. 80:749-756.
35. Ceriello A, Taboga C, Giacomello R, Falleti E, De Stasio G, Motz E, Lizzio S, Gonano F, Bartoli E. Fibrinogen plasma levels as a marker of thrombin activation in diabetes. Diabetes 1994. 43:430-432.
36. Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, Fontaine P, Jude B. Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 2001. 101:367-375.
37. De Lorenzo F, Mukherjee M, Kadziola Z, Suleiman S, Kakkar VV. Association of overall adiposity rather than body mass index with lipids and procoagulant factors. Thromb Haemost 1998. 80:603-606.
38. Chaderevian R, Bruckert E, Dejager S, Presberg P, Turpin G. Relationship between triglycerides and factor VIIc and plasminogen activator inhibitor type-1: lack of threshold value. Thromb Res 1999. 96:175-182.
39. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati M, Cordillo M, Catalano M, Gabrielli L, Lombardini B, Specchia G, Tavazzi L, Tremoli E, Pozzoli E, Turri M. Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case control study. Arterioscler Thromb 1993. 13:1412-1417.
40. Sakkineen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH, Tracy RP. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol 1999. 19:499-504.